20th July 2018
"Inote Morningstar analyst Chris Kallos updated his thoughts on CSLlast week, deciding the company's breakthrough medicinecandidate CSL112 is ready to be included in today's valuationmodeling, with the odds in favour of CSL launching the next potentialblockbuster addressing recurrent cardiovascular events in the first90 days following an initial heart attack by 2023. This area iscurrently not well covered by existing drug therapies and successwould grant CSL a significant first mover advantage.Morningstarhas decided fair value for CSL shares is now situated at $200, butsuccess with CSL112 can potentially move the dial to $250. Failurewould pull back fair value valuation to $140, all else remainingequal. In addition, favourable currency movements remain a keysensitivity for the shares with every 1c move in the AUD/USD crosstranslating into a $2 move in the share price."
https://www.livewiremarkets.com/wires/is-value-investing-now-dead
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$198.37 |
Change
0.030(0.02%) |
Mkt cap ! $96.23B | |||
| Open | High | Low | Value | Volume |
| $200.98 | $203.69 | $198.37 | $647.4M | 3.086M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 428 | $198.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $198.40 | 360 | 2 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| CSL (ASX) Chart |